Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) has been given a $50.00 price objective by Cantor Fitzgerald in a research note issued on Tuesday, October 17th. The brokerage currently has a “buy” rating on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s price objective indicates a potential upside of 123.71% from the company’s previous close.
A number of other research firms have also commented on PRTK. BidaskClub lowered shares of Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 23rd. Zacks Investment Research downgraded shares of Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 8th. HC Wainwright boosted their price objective on shares of Paratek Pharmaceuticals from $36.00 to $43.00 and gave the company a “buy” rating in a research report on Tuesday, July 18th. ValuEngine downgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, September 18th. Finally, Raymond James Financial, Inc. reissued a “strong-buy” rating and set a $36.00 price objective on shares of Paratek Pharmaceuticals in a research report on Thursday, August 24th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $40.00.
Paratek Pharmaceuticals (NASDAQ PRTK) traded down $0.05 during trading hours on Tuesday, reaching $22.35. 237,748 shares of the company were exchanged, compared to its average volume of 314,558. Paratek Pharmaceuticals has a 52 week low of $10.37 and a 52 week high of $29.00. The company has a debt-to-equity ratio of 0.43, a current ratio of 11.88 and a quick ratio of 11.88.
TRADEMARK VIOLATION NOTICE: “Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Given a $50.00 Price Target by Cantor Fitzgerald Analysts” was published by BBNS and is owned by of BBNS. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://baseballnewssource.com/markets/cantor-fitzgerald-analysts-give-paratek-pharmaceuticals-inc-prtk-a-50-00-price-target/1722316.html.
A number of hedge funds have recently made changes to their positions in PRTK. Russell Investments Group Ltd. purchased a new stake in Paratek Pharmaceuticals during the 1st quarter valued at about $211,000. Wells Fargo & Company MN grew its position in Paratek Pharmaceuticals by 9.9% during the 1st quarter. Wells Fargo & Company MN now owns 15,566 shares of the specialty pharmaceutical company’s stock valued at $300,000 after purchasing an additional 1,400 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Paratek Pharmaceuticals by 17.5% during the 1st quarter. Bank of New York Mellon Corp now owns 84,045 shares of the specialty pharmaceutical company’s stock valued at $1,618,000 after acquiring an additional 12,505 shares during the period. Victory Capital Management Inc. bought a new position in Paratek Pharmaceuticals during the 1st quarter valued at about $630,000. Finally, American International Group Inc. lifted its stake in Paratek Pharmaceuticals by 34.1% during the 1st quarter. American International Group Inc. now owns 11,111 shares of the specialty pharmaceutical company’s stock valued at $214,000 after acquiring an additional 2,824 shares during the period. 82.00% of the stock is currently owned by institutional investors.
Paratek Pharmaceuticals Company Profile
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.